Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.

Gordon SW, McGuire WP 3rd, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS.

Am J Clin Oncol. 2019 Aug;42(8):649-654. doi: 10.1097/COC.0000000000000567.

PMID:
31305287
2.

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS.

Gynecol Oncol. 2019 Aug;154(2):420-425. doi: 10.1016/j.ygyno.2019.05.013. Epub 2019 Jun 19.

PMID:
31229298
3.

Co-occurring substance use disorder: The impact on treatment adherence in women with locally advanced cervical cancer.

Rubinsak LA, Terplan M, Martin CE, Fields EC, McGuire WP, Temkin SM.

Gynecol Oncol Rep. 2019 Mar 27;28:116-119. doi: 10.1016/j.gore.2019.03.016. eCollection 2019 May.

4.

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.

McGuire WP, Penson RT, Gore M, Herraez AC, Peterson P, Shahir A, Ilaria R Jr.

BMC Cancer. 2018 Dec 27;18(1):1292. doi: 10.1186/s12885-018-5198-4.

5.

Treatment-Related Radiation Toxicity Among Cervical Cancer Patients.

Rubinsak LA, Kang L, Fields EC, Carter JS, McGuire WP, Temkin SM.

Int J Gynecol Cancer. 2018 Sep;28(7):1387-1393. doi: 10.1097/IGC.0000000000001309.

PMID:
30036222
6.

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future.

Fields EC, McGuire WP, Lin L, Temkin SM.

Front Oncol. 2017 Aug 21;7:177. doi: 10.3389/fonc.2017.00177. eCollection 2017. Review.

7.

Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.

Teng PN, Bateman NW, Wang G, Litzi T, Blanton BE, Hood BL, Conrads KA, Ao W, Oliver KE, Darcy KM, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Conrads TP.

Hum Cell. 2017 Jul;30(3):226-236. doi: 10.1007/s13577-017-0162-1. Epub 2017 Mar 1.

PMID:
28251557
8.

Phase I study of pemetrexed with sorafenib in advanced solid tumors.

Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE Jr, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P.

Oncotarget. 2016 Jul 5;7(27):42625-42638. doi: 10.18632/oncotarget.9434.

9.

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.

Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, Koromilas AE, Boone DL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 26;7(17):23608-32. doi: 10.18632/oncotarget.8281.

10.

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.

Tavallai M, Booth L, Roberts JL, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 5;7(14):17290-300. doi: 10.18632/oncotarget.8039.

11.

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.

Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P.

Oncotarget. 2016 Apr 12;7(15):19620-30. doi: 10.18632/oncotarget.7746.

12.

Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.

Webb T, Carter J, Roberts JL, Poklepovic A, McGuire WP, Booth L, Dent P.

Cancer Biol Ther. 2015;16(11):1660-70. doi: 10.1080/15384047.2015.1099769. Epub 2015 Sep 29.

13.

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J.

Gynecol Oncol. 2015 Jul;138(1):30-5. doi: 10.1016/j.ygyno.2015.04.005. Epub 2015 Apr 14.

14.

Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.

Bateman NW, Jaworski E, Ao W, Wang G, Litzi T, Dubil E, Marcus C, Conrads KA, Teng PN, Hood BL, Phippen NT, Vasicek LA, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Darcy KM, Conrads TP.

J Proteome Res. 2015 Apr 3;14(4):1900-10. doi: 10.1021/pr5012894. Epub 2015 Mar 19.

15.

Reply to T.j. Herzog et Al.

McGuire WP.

J Clin Oncol. 2015 May 1;33(13):1512. doi: 10.1200/JCO.2014.60.3571. Epub 2015 Mar 2. No abstract available.

PMID:
25732173
16.

Ovarian cancer and antiangiogenic therapy: caveat emptor.

Oliver KE, McGuire WP.

J Clin Oncol. 2014 Oct 20;32(30):3353-6. doi: 10.1200/JCO.2014.57.4574. Epub 2014 Sep 15. No abstract available.

PMID:
25225422
17.

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP.

Gynecol Oncol. 2014 Sep;134(3):478-85. doi: 10.1016/j.ygyno.2014.06.029. Epub 2014 Jul 10.

18.

Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.

Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP.

J Cancer. 2014 Jan 1;5(1):25-30. doi: 10.7150/jca.7810. Review.

19.

HE4--another marker for gynecologic cancers: do we really need one?

McGuire WP.

Oncology (Williston Park). 2013 Jun;27(6):563, 566. No abstract available.

20.

Another confirmation of the inactivity of topotecan in ovarian cancer.

McGuire WP.

J Natl Cancer Inst. 2010 Oct 20;102(20):1523-4. doi: 10.1093/jnci/djq387. Epub 2010 Oct 11. No abstract available.

PMID:
20937989
21.
22.

Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.

McGuire WP.

J Clin Oncol. 2009 Oct 1;27(28):4633-4. doi: 10.1200/JCO.2009.23.6653. Epub 2009 Aug 24. No abstract available.

PMID:
19704055
23.

Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP, Birrer MJ.

Gynecol Oncol. 2009 Sep;114(3):472-9. doi: 10.1016/j.ygyno.2009.05.012. Epub 2009 Jun 12.

24.

Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.

Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, McGuire WP, Hanjani P, Warshal D, Greer BE, Belinson J, Birrer MJ.

Gynecol Oncol. 2009 Jun;113(3):341-7. doi: 10.1016/j.ygyno.2009.02.009. Epub 2009 Mar 9.

PMID:
19272639
25.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM.

J Clin Oncol. 2009 Mar 20;27(9):1419-25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 May 1;27(13):2305.

26.

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK.

Cancer. 2009 Apr 1;115(7):1395-403. doi: 10.1002/cncr.24152. Review.

27.

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK.

Cancer. 2009 Mar 1;115(5):1028-35. doi: 10.1002/cncr.24084.

28.

Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.

Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T, Farley JH; Gynecologic Oncology Group.

Gynecol Oncol. 2008 Dec;111(3):487-95. doi: 10.1016/j.ygyno.2008.08.020. Epub 2008 Oct 2.

29.

Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?

Tummala MK, Alagarsamy S, McGuire WP.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1135-47. doi: 10.1586/14737140.8.7.1135. Review.

PMID:
18588458
30.

Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.

Hooker AC, Ten Tije AJ, Carducci MA, Weber J, Garrett-Mayer E, Gelderblom H, McGuire WP, Verweij J, Karlsson MO, Baker SD.

Clin Pharmacol Ther. 2008 Jul;84(1):111-8. doi: 10.1038/sj.clpt.6100476. Epub 2008 Jan 9.

31.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):83-9. Epub 2007 Nov 19.

PMID:
18025437
32.

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP; Gynecologic Oncology Group Study.

J Clin Oncol. 2007 Aug 20;25(24):3621-7.

PMID:
17704411
33.

Ovarian cancer, CA-125 addiction, and informed confusion: much ado about less.

Tummala MK, McGuire WP.

J Clin Oncol. 2007 Aug 20;25(24):3570-1. No abstract available.

PMID:
17704402
34.

Ovarian cancer and the battle of the specialists.

McGuire WP.

J Clin Oncol. 2007 Aug 10;25(23):3554-5; author reply 3557-8. No abstract available.

PMID:
17687166
35.

Is it time for some new approaches for treating advanced ovarian cancer?

McGuire WP.

J Natl Cancer Inst. 2006 Aug 2;98(15):1024-6. No abstract available.

PMID:
16882933
36.

CASE 1. Testis: a sanctuary site in Merkel cell carcinoma.

Tummala MK, Hausner PF, McGuire WP, Gipson T, Berkman A.

J Clin Oncol. 2006 Feb 20;24(6):1008-9. No abstract available.

PMID:
16484705
37.

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP 3rd.

Gynecol Oncol. 2006 Apr;101(1):55-61. Epub 2005 Nov 2.

PMID:
16260029
38.

Recurrent ovarian cancer.

Tummala MK, McGuire WP.

Clin Adv Hematol Oncol. 2005 Sep;3(9):723-36.

PMID:
16224447
39.

CA-125 and early ovarian cancer: does this help the clinician or further muddy the water?

McGuire WP.

J Clin Oncol. 2005 Sep 1;23(25):5862-4. Epub 2005 Aug 8. No abstract available.

PMID:
16087955
40.

Liposomal anthracycline treatment for ovarian cancer.

Markman M, Gordon AN, McGuire WP, Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 13):91-105. Review.

PMID:
15717739
41.

Factors affecting cytochrome P-450 3A activity in cancer patients.

Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A.

Clin Cancer Res. 2004 Dec 15;10(24):8341-50.

42.

Perioperative morbidity and the rush to chemotherapy.

McGuire WP 3rd.

J Clin Oncol. 2005 Feb 1;23(4):665-6. Epub 2004 Dec 21. No abstract available.

PMID:
15613693
43.

Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.

Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP.

J Support Oncol. 2003 Jul-Aug;1(2):131-8.

PMID:
15352656
44.

Primary ovarian cancer chemotherapy: current standards of care.

McGuire WP 3rd, Markman M.

Br J Cancer. 2003 Dec;89 Suppl 3:S3-8. Review.

45.

Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.

Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE; Gynecologic Oncology Group.

J Clin Oncol. 2003 Nov 15;21(22):4207-13.

PMID:
14615449
46.

Current status of taxane and platinum-based chemotherapy in ovarian cancer.

McGuire WP 3rd.

J Clin Oncol. 2003 May 15;21(10 Suppl):133s-135s. Review.

PMID:
12743128
47.

Progress in the management of gynecologic cancer: consensus summary statement.

Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L.

J Clin Oncol. 2003 May 15;21(10 Suppl):129s-132s. No abstract available.

PMID:
12743127
48.

Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.

Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.

Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):31-6.

49.

Chemotherapy for advanced epithelial ovarian carcinoma.

Kalil NG, McGuire WP.

Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):553-71. Review.

PMID:
12413934
50.

Contemporary management of ovarian cancer.

Im DD, McGuire WP, Rosenshein NB.

Obstet Gynecol Clin North Am. 2001 Dec;28(4):759-73. Review.

PMID:
11766150

Supplemental Content

Loading ...
Support Center